Zenotech Laboratories Ltd

Zenotech Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant downturn in its financial performance for the quarter ended March 2026. The company’s key metrics, including net sales, profit after tax, and operating margins, have all deteriorated sharply compared to its recent historical averages, signalling a shift from positive to negative financial trends.

Zenotech Laboratories Ltd., a micro-cap pharmaceutical company specialising in generic injectables for oncology and anaesthesiology, reported a concerning quarter ending March 2026, with net profit plunging into negative territory at ₹-3.15 crores—a dramatic reversal from ₹1.93 crores in Q3 FY26. The company, with a market capitalisation of ₹281.00 crores, saw its stock trading at ₹45.53 as of April 29, 2026, reflecting a marginal 0.22% gain in the session following the results announcement, though the broader picture reveals significant underlying operational challenges.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 04 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

While the broader market showed signs of recovery, Zenotech Laboratories Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 33.55 on 30 Mar 2026. This decline comes amid a backdrop of underperformance relative to both its sector and benchmark indices.

For the third consecutive session, Zenotech Laboratories Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 34.5 on 27 Mar 2026. This marks a significant 52.7% drop from its peak of Rs 72.87 within the last year, underscoring persistent selling pressure despite some recent operational improvements.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Zenotech Laboratories Ltd’s share price declined sharply to a fresh 52-week low of Rs.34.99 on 23 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low comes amid a broader market weakness and persistent underperformance relative to its sector and benchmark indices.

Zenotech Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.40.01 today, marking a significant milestone in its recent price trajectory amid broader market weakness and sectoral pressures.

Zenotech Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.40.5 today, marking a significant milestone in its recent price trajectory. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures and valuation concerns.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Zenotech Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.42.01 on 9 March 2026, marking a significant price level amid ongoing market pressures and company-specific factors. The stock underperformed its sector and broader indices, reflecting persistent challenges in its valuation and performance metrics.

Zenotech Laboratories Ltd’s shares touched a fresh 52-week low of Rs.42.05 today, marking a significant decline amid continued underperformance relative to its sector and benchmark indices. The stock has now recorded losses over four consecutive trading sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Zenotech Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.43 today, marking a significant price level for the pharmaceutical and biotechnology company amid a broader market environment that saw mixed movements.

Zenotech Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.43 today, marking a significant price level for the pharmaceutical and biotechnology company amid a series of recent declines and ongoing market pressures.